There is no better tap than ARS Pharmaceuticals Inc (SPRY) Stock

Leerink Partners raised the price target for the ARS Pharmaceuticals Inc (NASDAQ:SPRY) stock from “a Market perform” to “an Outperform”. The rating was released on March 05, 2024, according to finviz. The stock was initiated by Wedbush, who disclosed in a research note on January 31, 2023, to Outperform and set the price objective to […]

ARS Pharmaceuticals Inc (SPRY) Stock Is Looking Attractive

Leerink Partners raised the price target for the ARS Pharmaceuticals Inc (NASDAQ:SPRY) stock from “a Market perform” to “an Outperform”. The rating was released on March 05, 2024, according to finviz. The stock was initiated by Wedbush, who disclosed in a research note on January 31, 2023, to Outperform and set the price objective to […]

Top-line Growth is Likely to Be Driven by ARS Pharmaceuticals Inc (SPRY) Stock

Leerink Partners raised the price target for the ARS Pharmaceuticals Inc (NASDAQ:SPRY) stock from “a Market perform” to “an Outperform”. The rating was released on March 05, 2024, according to finviz. The stock was initiated by Wedbush, who disclosed in a research note on January 31, 2023, to Outperform and set the price objective to […]

Why ARS Pharmaceuticals Inc (NASDAQ:SPRY) Stock rose 88.66% in Last Six Months?

Leerink Partners raised the price target for the ARS Pharmaceuticals Inc (NASDAQ:SPRY) stock from “a Market perform” to “an Outperform”. The rating was released on March 05, 2024, according to finviz. The stock was initiated by Wedbush, who disclosed in a research note on January 31, 2023, to Outperform and set the price objective to […]